What's Happening?
Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech company, has successfully closed a Series B financing round, raising over $31 million. The funding was co-led by an undisclosed strategic investor
and S3 Ventures, with participation from the T45 Fund and other investors. ANT is developing a dual-drug nanoparticle-coated balloon platform for vascular treatment, which aims to improve outcomes for patients with coronary and peripheral artery disease. This innovative approach uses a combination of paclitaxel and sirolimus to enhance therapeutic effects and provide a more predictable vascular response compared to existing single-drug coated balloons. The technology, licensed from Cleveland Clinic, has received FDA breakthrough designation and is currently under clinical evaluation.
Why It's Important?
The successful funding round positions ANT to advance its novel vascular treatment technology, which could significantly impact the medical field by offering a new category of drug-coated balloon therapy. This development is crucial as it addresses the limitations of current treatments and aims to reduce restenosis, a common issue following percutaneous coronary intervention. The dual-drug delivery system promises to enhance patient outcomes by providing sustained drug retention at lower doses, potentially reducing the need for repeat procedures. The advancement of this technology could lead to improved healthcare delivery and patient care, particularly in treating coronary and peripheral artery diseases.
What's Next?
ANT plans to use the funds to scale up manufacturing to meet FDA Investigational Device Exemption (IDE) requirements and advance its clinical programs. The company aims to submit U.S. IDE applications for two coronary indications and complete testing for a U.S. below-the-knee early feasibility study. ANT is also pursuing a pivotal clinical trial agreement with the FDA and identifying clinical sites for early pivotal enrollment. These steps are critical for bringing the dual-drug nanoparticle-coated balloon platform to market and providing patients with better treatment options.
